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Abstract: Two new jaspamide derivatives 2 and 3, together with the parent compound 
jaspamide (1) have been isolated from the marine sponge Jaspis splendens collected in 
Kalimantan (Indonesia). The structures of the new compounds were unambiguously 
elucidated based on 1D and 2D NMR spectral data, mass spectrometry and comparison 
with jaspamide (1). The new derivatives inhibited the growth of mouse lymphoma 
(L5178Y) cell line in vitro with IC50 values of <0.1 µg/mL. 
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1.  Introduction 
 
Peptides are well-known bioactive metabolites from marine invertebrates [1,2] including linear 
peptides [3,4], depsipeptides [5,6], cyclic [7–11] and bicyclic peptides [12,13]. Sponges of the genus 
Jaspis (family, Jaspidae) have been a rich source of biologically active, structurally novel natural 
products. After the discovery of the cyclodepsipeptide jaspamide (jasplakinolide, 1) in the sponge 
Jaspis cf. johnstoni in 1986 by Ireland [14] and Crews [15], which is known for its pronounced 
biological activities including antifungal [16], anthelmintic, insecticidal [14,15] and cytotoxic   
activity [17], sponges of the genus Jaspis have received considerable attention, and since then the 
chemistry of Jaspis sponges has been the subject of more than 90 publications. A wide variety of 
constituents has been isolated from this genus including several jaspamide derivatives from Jaspis 
splendens  [18–21], isomalabaricane triterpenes from Jaspis stellifera [22–24] and other   
species [25–29], cytotoxic macrolides from the Okinawan sponge Jaspis sp. [30], bengazoles [31,32] 
that stand out as unique bis-oxazoles containing a carbohydrate-like polyol side chain, antiparasitic, 
antimicrobial, and cytotoxic amino acid derivatives known as bengamides [33–35], cytotoxic 
bromotyrosine derivatives [36,37], and a series of dihydroxystyrene sulphate derivatives [38–42]. 
 
Figure 1. New jaspamide derivatives 2 and 3, together with the parent jaspamide (1). 
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R1= Br, R2= H:  Jaspamide (1)    
R1, R2= H:   Jaspamide Q (2) 
R1, R2= Br:   Jaspamide R (3) 
 
As part of our ongoing studies on bioactive natural products from marine sponges, we investigated 
a specimen of Jaspis splendens collected in Kalimantan (Indonesia). The crude methanolic extract 
exhibited considerable in vitro cytotoxic activity against mouse lymphoma L5178Y cells. 
Chromatographic separation of the extract yielded jaspamide (1) as the major constituent. Through 
bioactivity-guided chemical investigation of the ethyl acetate soluble fraction minor analogues of 
jaspamide, including the new natural products jaspamide Q (2), and jaspamide R (3) (Figure 1) were 
obtained. In this paper, we describe isolation, structural elucidation, and biological activity of the new Mar. Drugs 2009, 7 
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jaspamide derivatives, both of which carry a modified 2-bromoabrine (N-methyltryptophan) residue 
compared to jaspamide (1). 
 
2.  Results and Discussion 
 
Total methanolic extract of the sponge J. splendens was partitioned according to the scheme 
previously described by Ebada et al. [43]. The bioactive ethyl acetate soluble fraction was further 
chromatographed by Sephadex LH20 column chromatography followed by reversed-phase preparative 
HPLC to give jaspamide (1, 0.0013%, dry weight), jaspamide Q (2, 0.00001%, dry weight), and 
jaspamide R (3, 0.00001%, dry weight). 
Jaspamide Q (2) was obtained as a white amorphous solid, and the ESIMS spectrum showed a 
pseudomolecular ion peak at m/z 631.3 [M+H]
+, which was 79 amu smaller than that of jaspamide (1), 
the parent compound. This difference was assigned to the absence of the bromine atom at C-26 in 
jaspamide (1). The molecular formula of jaspamide Q (2) was C36H46N4O6, based on HRFTMS   
(m/z 631.3491 [M+H]
+,  ∆ + 1.0 ppm), therefore jaspamide Q (2) was identified as the debromo 
analogue of 1. 
1H-NMR spectral data (Table 1) revealed that the resonances of 2 were superimposable 
with those of 1 with only one additional proton resonance at δH 6.87 (1H, br s) that was ascribed to  
H-26. The complete structure of jaspamide Q (2) was unambiguously elucidated and assigned on the 
basis of 
1H–
1H COSY, TOCSY, ROESY, and HMBC spectra.  
In particular, the similarity of 
1H-, and
 13C-NMR resonances between jaspamide Q (2) and 
jaspamide (1) implied that the chiral centers of alanine, abrine (N-methyltryptophan), ß-tyrosine, and 
of the polypropionate fragment had the same relative configurations in both molecules. Therefore, the 
stereochemistry depicted in Figure 1 was tentatively assigned by analogy with the parent compound 
together with ROESY spectra that revealed a clear correlation between Me-16 and Me-34; and Me-33 
and Me-36. However, an apparent deshielding of Me-16 was noted in 2 [δH 1.04 (3H, d, 6.6 Hz)] 
compared to 1  [δH 0.70 (3H, d, 6.7 Hz)] resembling that between jaspamide M [δH 1.17 (3H, d,  
6.8 Hz)] [21] and jaspamide H [δH 0.72 (3H, d, 6.7 Hz)] [20]. These differences in chemical shifts for 
the latter congeners were proven to be caused by D-Ala or L-Ala residues, respectively. Anaylsis of the 
absolute configurations of the amino acids of 2 could not be performed due to the small amount of 
compound isolated (0.7 mg). 
A partial 
13C-NMR assignment of jaspamide Q (2) was achieved through HMBC spectra (Figure 2) 
which revealed clear correlations at δc 174.5, δc 40.4, δc 40.9, δc 133.6, δc 128.2, δc 29.5, δc 43.6,  
δc 70.4, δc 56.4, δc 173.6, and δc 46.0 ppm that were ascribed to C-1 to C-8, and C-13 to C-15, 
respectively. Moreover, HMBC spectra evidenced and confirmed the amino acid sequence in 
jaspamide Q (2) through cross-peaks between NH-Tyr and C-12, Me-17 and C-14, and between   
NH-Ala and C-1. 
Jaspamide R (3) was isolated as a white amorphous solid. Its ESI mass spectrum exhibited 
pseudomolecular ion peaks at m/z 787.1, 789.1, and 791.1 [M+H]
+, in a ratio of 1:2:1, supporting the 
existence of two bromine atoms in the compound. The molecular formula of jaspamide R (3) was 
determined to be C36H44Br2N4O6 by HRFTMS (m/z 789.1691 [M+H]
+, ∆ + 1.0 ppm) which exceeds 
that of jaspamide (1) by 79 amu revealing that jaspamide R (3) is a dibromo analogue of   
jaspamide Q (2). Mar. Drugs 2009, 7 
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Figure 2. Key HMBC correlations of jaspamide Q (2). 
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This difference was explained by the 
1H-NMR spectral data (Table 1), which revealed close 
similarity between jaspamide R (3) and jaspamide (1), except for the proton resonances corresponding 
to the indole moiety of the 2-bromoabrine unit. Jaspamide R (3) showed three proton resonances at  
δH 7.41 (1H, br s), δH 7.20 (1H, d, 8.2 Hz), and δH 7.42 (1H, d, 8.2 Hz) that were assigned to H-21,  
H-23, and H-24, respectively. Whereas for jaspamide (1), four resonances, at δH 7.23 (1H, d, 8.0 Hz),  
δH 7.10 (1H, t, 8.0 Hz), δH 7.12 (1H, t, 8.0 Hz), and δH 7.54 (1H, d, 8.0 Hz), ascribed for H-21 to H-24, 
were observed. Based on this finding, the additional bromine atom of 3 was assumed to be located at 
C-22. This hypothesis was further confirmed by 2D NMR spectral analyses including 
1H–
1H COSY, 
TOCSY, and NOESY spectra that revealed a clear NOE correlation between proton resonance at   
δH 7.41 (1H, br s), and NH-Tyr at δH 7.53 (1H, d, 8.6 Hz) proving the attachment of the second 
bromine atom to be at C-22. Moreover, the close resemblance in 
1H resonances between jaspamide R 
(3), and jaspamide (1) supports the notion that the chiral centers of alanine, 2,4-dibromoabrine,   
ß-tyrosine, and the polypropionate fragment have the same relative configurations in both molecules 
(Figure 1). Again, due to the lack of material isolated of 3 (0.5 mg), analysis of the absolute 
configurations of the amino acids, e.g. by Marfey’s method, could not be performed.   
To the best of our knowledge, fifteen jaspamide congeners (B–P) were hitherto isolated from the 
genus Jaspis [14,18–21] and all of them show antiproliferative activity with IC50 values ranging from 
0.01 to 33 µM against human breast adenocarinoma (MCF-7), and colon carcinoma (H-29) cell   
lines [21].  
Jaspamide Q (2) and R (3) together with the parent jaspamide (1) differ in the bromination pattern 
of the abrine (N-methyltryptophan) moiety. Since these modifications were claimed as essential for the 
observed biological activity [44], compounds (2 and 3) together with jaspamide (1) were subjected to a 
cytotoxicity (MTT) assay against mouse lymphoma (L5178Y) cell lines. They exhibited potent 
activities with IC50 values in the ng/mL range (<0.1 µg/mL, <0.16 µM), compared to kahalalide F 
(IC50 = 6.3 µg/mL, 4.3 µM) which was used as a positive control. Further studies aimed at determining 
the effect of bromination pattern of the abrine residue on cytototoxic activity are in progress. 
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Table 1. 
1H-NMR data of jaspamide Q (2), and R (3), (500 MHz, CDCl3-d). 
Position 
Jaspamide Q (2)     Jaspamide R (3)  
δH mult. (J Hz)    δH mult. (J Hz) 
2  2 2. .5 51 1   ( (1 1H H, , m m) )       2 2. .4 49 9 ( (1 1H H, , m m) )  
3  A A) )   2 2. .3 37 7   ( (1 1H H, ,   d dd d, ,   1 11 1. .5 5, ,   1 15 5. .8 8   H Hz z) ) 
B B) )   1 1. .9 90 0   ( (1 1H H, ,   d d, ,   1 15 5. .8 8   H Hz z) )  
    A A) )   2 2. .3 37 7   ( (1 1H H, ,   d dd d, ,   1 11 1. .5 5, ,   1 15 5. .8 8   H Hz z) ) 
B B) ) 1 1. .9 90 0 ( (1 1H H. . d d, , 1 15 5. .8 8   H Hz z) )    
5  4 4. .7 79 9   ( (1 1H H, , d d, ,   6 6. .7 7   H Hz z) )       4 4. .7 74 4 ( (1 1H H, , d d, , 6 6. .7 7 H Hz z) )    
6  2 2. .2 23 3   ( (1 1H H, , m m) )       2 2. .2 23 3 ( (1 1H H, , m m) )  
7  A A) )   1 1. .3 32 2   ( (1 1H H, ,   m m) ), ,   B B) )   1 1. .1 10 0 ( (1 1H H, , m m) )     A A) ) 1 1. .3 32 2 ( (1 1H H, , m m) ), , B B) )   1 1. .1 10 0   ( (1 1H H, ,   m m) )  
8  4 4. .6 64 4   ( (1 1H H, , m m) )       4 4. .6 60 0 ( (1 1H H, , m m) )  
10  A A) )   2 2. .6 67 7   ( (1 1H H, ,   d dd d, ,   4 4. .7 7, ,   1 15 5. .0 0   H Hz z) ) 
B B) )   2 2. .6 61 1   ( (1 1H H, ,   d dd d, ,   5 5. .7 7, ,   1 14 4. .8 8 H Hz z) )  
    A A) )   2 2. .6 67 7   ( (1 1H H, ,   d dd d, ,   4 4. .7 7, ,   1 15 5. .0 0   H Hz z) ) 
B B) ) 2 2. .6 61 1 ( (1 1H H, , d dd d, , 5 5. .7 7, ,   1 14 4. .8 8   H Hz z) )    
11  5 5. .2 25 5   ( (1 1H H, ,   d dd d, ,   5 5. .3 3, ,   8 8. .6 6   H Hz z) )         5 5. .2 25 5   ( (1 1H H, ,   d dd d, ,   5 5. .3 3, ,   8 8. .6 6   H Hz z) )    
13  5 5. .6 63 3   ( (1 1H H, ,   d dd d, ,   6 6. .3 3, ,   1 10 0. .0 0   H Hz z) )         5 5. .7 73 3   ( (1 1H H, ,   d dd d, ,   6 6. .3 3, ,   1 10 0. .0 0   H Hz z) )    
15  4 4. .7 77 7   ( (1 1H H, ,   m m) )         4 4. .7 72 2   ( (1 1H H, ,   m m) )    
16  1 1. .0 04 4   ( (3 3H H, ,   d d, ,   6 6. .6 6   H Hz z) )         0 0. .8 81 1   ( (3 3H H, ,   d d, ,   6 6. .7 7   H Hz z) )    
17  2 2. .9 97 7   ( (3 3H H, ,   s s) )         2 2. .9 98 8   ( (3 3H H, ,   s s) )    
18  A A) )   3 3. .4 43 3   ( (1 1H H, ,   d dd d, ,   6 6. .3 3, ,   1 15 5. .5 5   H Hz z) ) 
B B) )   3 3. .1 17 7   ( (1 1H H, ,   d dd d, ,   1 10 0. .4 4, ,   1 15 5. .2 2 H Hz z) )  
    A A) )   3 3. .3 33 3   ( (1 1H H, ,   d dd d, ,   6 6. .3 3, ,   1 15 5. .5 5   H Hz z) ) 
B B) ) 3 3. .1 18 8 ( (1 1H H, , d dd d, , 1 10 0. .4 4, ,   1 15 5. .2 2   H Hz z) )    
21  7 7. .6 61 1   ( (1 1H H, ,   d d, ,   8 8. .0 0   H Hz z) )         7 7. .4 41 1   ( (1 1H H, ,   b br r   s s) )    
22  7 7. .1 11 1   ( (1 1H H, , t t, ,   8 8. .0 0   H Hz z) )        
23  7 7. .1 18 8   ( (1 1H H, , t t, ,   8 8. .0 0   H Hz z) )       7 7. .2 20 0 ( (1 1H H, , d d, , 8 8. .2 2 H Hz z) )    
24  7 7. .3 35 5   ( (1 1H H, , d d, ,   8 8. .0 0   H Hz z) )   7 7. .4 42 2 ( (1 1H H, , d d, , 8 8. .2 2 H Hz z) )    
26  6 6. .8 87 7   ( (1 1H H, , b br r   s s) )        
28  6 6. .9 90 0   ( (1 1H H, , d d, ,   8 8. .3 3   H Hz z) )       6 6. .9 98 8 ( (1 1H H, , d d, , 8 8. .4 4 H Hz z) )    
29  6 6. .6 69 9   ( (1 1H H, , d d, ,   8 8. .3 3   H Hz z) )       6 6. .7 71 1 ( (1 1H H, , d d, , 8 8. .4 4 H Hz z) )    
31  6 6. .6 69 9   ( (1 1H H, ,   d d, ,   8 8. .3 3   H Hz z) )         6 6. .7 71 1   ( (1 1H H, ,   d d, ,   8 8. .4 4   H Hz z) )    
32  6 6. .9 90 0   ( (1 1H H, ,   d d, ,   8 8. .3 3   H Hz z) )           6 6. .9 98 8   ( (1 1H H, ,   d d, ,   8 8. .4 4   H Hz z) )    
33  1 1. .0 06 6   ( (3 3H H, ,   d d, ,   6 6. .3 3   H Hz z) )         1 1. .0 05 5   ( (3 3H H, ,   d d, ,   6 6. .1 1   H Hz z) )    
34  0 0. .8 83 3   ( (3 3H H, ,   d d, ,   6 6. .5 5   H Hz z) )         0 0. .8 81 1   ( (3 3H H, ,   d d, ,   6 6. .7 7   H Hz z) )    
35  1 1. .5 59 9   ( (3 3H H, ,   s s) )         1 1. .5 57 7   ( (3 3H H, ,   s s) )    
36  1 1. .1 15 5   ( (3 3H H, ,   d d, ,   6 6. .8 8   H Hz z) )         1 1. .1 13 3   ( (3 3H H, ,   d d, ,   6 6. .8 8   H Hz z) )    
NH-Tyr  7 7. .4 46 6   ( (1 1H H, ,   d d, ,   8 8. .6 6   H Hz z) )      7 7. .5 53 3   ( (1 1H H, ,   d d, ,   8 8. .6 6   H Hz z) )    
NH-Trp  8 8. .2 24 4   ( (1 1H H, ,   b br r   s s) )         8 8. .4 42 2   ( (1 1H H, ,   b br r   s s) )    
NH-Ala  6 6. .7 73 3   ( (1 1H H, ,   d d, ,   6 6. .4 4   H Hz z) )         6 6. .6 65 5   ( (1 1H H, ,   d d, ,   6 6. .5 5   H Hz z) )    
 
3.  Experimental Section  
 
General experimental procedures  
 
Column chromatography was carried out on Sephadex LH-20 using methanol as an eluent. For 
analytical HPLC analysis, samples were injected into a HPLC system equipped with a photodiode 
array detector (Dionex, Munich, Germany). Routine detection was at 235, 254, 280, and 340 nm. The 
separation column (125 × 4 mm ID) was prefilled with C-18 Eurosphere, 5 µm (Knauer, Berlin, 
Germany). Separation was achieved by applying a linear gradient from 90% H2O (pH 2.0) to   Mar. Drugs 2009, 7 
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100% MeOH over 40 min. TLC analysis was carried out using aluminium sheet precoated with silica 
gel 60 F254 (Merck, Darmstadt, Germany).  
Preparative HPLC separations were performed on a LaChrom-Merck Hitachi HPLC system, pump 
L-7100, UV detector L-7400 using a C-18 column (Knauer, 300 × 8 mm ID, prefilled with C-18 
Eurosphere, flow rate 5 mL/min, UV detection at 280 nm), and the solvent system consisted of a linear 
gradient of MeOH and nanopure H2O.  
Optical rotations were measured on a Perkin-Elmer-241 MC polarimeter. ESIMS were obtained on 
a ThermoFinnigan LCQ DECA mass spectrometer coupled to an Agilent 1100 HPLC system equipped 
with a photodiode array detector. HRFTMS was recorded on a LTQ FT-MS-Orbitrap 
(ThermoFinnigan, Bremen, Germany). 1D and 2D NMR spectra were recorded at 300 ºK on a Bruker 
ARX-500. Samples were dissolved in deuterochloroform. 
 
Biological material  
 
In August 2008, specimens of J. splendens were collected on three neighboring Islands from East 
Kalimantan (Indonesia), namely Samama, Panjang, and Shoal Islands, at 10 meter depths. Numbers of 
voucher specimens are RMNH Por. 4234, 4266 and 4299, respectively. They were taxonomically 
identified as Jaspis splendens (order Astrophorida, family Ancorinidae) at the National Museum of 
Natural History, Leiden, Netherlands. HPLC and LCMS analyses of the three samples revealed that 
they were identical with regard to their peptide derivatives. Hence, the material was combined in order 
to obtain sufficient amounts of compounds for subsequent structure elucidation.  
 
Extraction and isolation  
 
The animal was freeze-dried, and the material (500 g) was extracted with methanol (3 × 2 L) and 
filtered. The extract was then combined, evaporated to dryness, and partitioned as follows. The 
methanolic extract (80 g) was dissolved in water and partitioned against n-hexane, ethyl acetate, and 
then n-butanol. The bioactive ethyl acetate soluble fraction (2 g) was chromatographed by CC using 
Sephadex LH20 as stationary phase and eluted with methanol followed by reversed-phase   
(C18 Eurosphere 100) HPLC using gradient elution of MeOH:H2O to yield 105 mg of jaspamide (1), 
0.7 mg of jaspamide Q (2), and 0.5 mg of jaspamide R (3). 
 
Jaspamide Q (2) was obtained as a white amorphous solid:  
20
D   -62.0° (c 0.01, CHCl3); UV (MeOH) 
λmax 226, 280 nm; 
1H-NMR see Table 1; ESI-MS pos m/z 631.3 [M+H]
+ (100), ESI-MS neg m/z 629.3 
[M-H]
- (100), HRFTMS m/z 631.3491 [M+H]
+ (calcd for C36H47N4O6, 631.3490), and m/z 653.3307 
[M+Na]
+ (calcd for C36H46N4O6Na, 653.3310).  
 
Jaspamide R (3) was obtained as a white amorphous solid:  
20
D   -100.0° (c 0.01, CHCl3); UV (MeOH) 
λmax 231, 283 nm; 
1H-NMR see Table 1; ESI-MS pos m/z 787.1, 789.1, 791.1 [M+H]
+, 1:2:1; ESI-MS 
neg  m/z 785.2, 787.1, 789.0 [M-H]
-, 1:2:1; HRFTMS m/z 789.1691 [M+H]
+ (calcd for 
C36H45N4O6
79Br2, 789.1680), and m/z 811.1507 [M+Na]
+ (calcd for C36H44N4O6
79Br2Na, 811.1499). 
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Cell proliferation assay 
 
Cytotoxicity was tested against L5178Y mouse lymphoma cells using the microculture tetrazolium 
(MTT) assay as described earlier [11,45]. All experiments were carried out in triplicate and repeated 
three times. As controls, media with 0.1% EGMME/DMSO were included in the experiments.
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